Clinical Trial – Participate

• Participant must be ≥ 18 years of age
• Have had symptoms for 3 days or less
• You will receive study medication for your UTI
• Study-related care from a local doctor
• Compensation for time and travel
• View Clinical Trial Flyer

Compensation: Reimbursement Available

• Vesair® Bladder Control System
• Post-Menopausal Females
• Experience urine leakage when you laugh, cough, sneeze, or during exercise

Compensation: Please Inquire

• Participant must be between 20 and 70 years of age
• Negative urine test for urinary tract infection (UTI) at time of enrollment
• No history of UTI or mixed incontinence with a predominant urge component
• Study-related care from a local doctor
• Compensation for time and travel
• View Clinical Trial Flyer

Compensation: Reimbursement Available

• • Participant must be ≥ 18 years of age
  • High-risk, non-muscle-invasive bladder cancer
  • Prior treatment with Intravesical BCG therapy no response to treatment
  • Fast and frequent access to a local urologist with no wait 
  • Compensation for time and travel
  • View Clinical Trial Information

Compensation: Reimbursement Available

• Participant must be ≥ 18 years of age
• High-risk, non-muscle-invasive bladder cancer
• No prior treatment with Intravesical BCG therapy within two years
• Fast and frequent access to a local urologist with no wait 
• Compensation for time and travel
• View Clinical Trial Information

Compensation: Reimbursement Available

• A clinical research study is being conducted for adults with Bladder Cancer
• Participant must be ≥ 18 years of age
• No health insurance required
• Must not have an active UTI
• Study medications and examinations are at no cost
• Compensation for time and travel
• View Clinical Trial Information

• Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
• View Clinical Trial Information

• Participant must be between 50 and 70 years of age
• Never received treatment for prostate cancer
• Healthy enough for sexual activity
• $100 gift card when you submit the sample
• View Clinical Trial Flyer

Compensation: $100 gift card

• Participant must be ≥ 18 years of age
• Metastatic prostate cancer disease
• No prior treatment with chemotherapy is permitted
• Fast and frequent access to a local urologist with no wait
• Compensation for time and travel
• View Clinical Trial Flyer

Compensation: Reimbursement Available

• Participant must be ≥ 18 years of age
• Cancer must have spread to other parts of the body (metastatic disease)
• Prior treatment with at least one second-generation androgen blocking therapy (i.e., abiraterone acetate or enzalutamide)
• Fast and frequent access to a local urologist with no wait
• Compensation for time and travel

Compensation: Reimbursement Available

• Participant must be ≥ 18 years of age
• Cancer must have spread to other parts of the body (metastatic disease)
• You must have prostate cancer that is castration-resistant, meaning it cannot be cured by either surgery or hormone therapy
• Fast and frequent access to a local urologist with no wait 
• Compensation for time and travel
• View Clinical Trial Information

Compensation: Reimbursement Available

• Participant must be ≥ 45 years of age
• Agree to continue to stay on a stable dose of BPH treatment
• No prostatitis in the past 6 months
• Study-related care from a local doctor
• Compensation for time and travel
• View Clinical Trial Flyer

Compensation: Reimbursement Available

• A clinical research study is being conducted for adults with low-grade non-muscle-invasive bladder cancer (NMIBC)
• Participant must be ≥ 18 years of age
• Low-grade NMIBC meets certain criteria
  
• Blood test results that show adequate liver, kidney, and bone marrow function
• Must not have an active UTI
• Contact us to find out if you qualify.
• Study medications and examinations are at no cost
• Compensation for time and travel
• View Clinical Trial Information

• Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Prior Treatment with at Least One Androgen Receptor Targeting Agent
• Please watch video for additional information: